Population pharmacokinetics and dosing optimization of latamoxef in neonates and young infants
Latamoxef (moxalactam) is a second-generation semi-synthetic oxacephem antibiotic that has been primarily used against Gram-positive and -negative aerobic, as well as anaerobic, bacteria [1]. This drug has been used for the treatment of adults, children, infants, and neonates since it was first introduced to clinical medicine in 1981 [2]. With the development of other novel antibiotics, use of latamoxef for treatment of infectious diseases in newborns was reduced. However, as the prevalence of antibiotic-resistant bacterial strains has increased significantly, there has been recent renewed interest in historical antibiotics [3].
Source: International Journal of Antimicrobial Agents - Category: Drugs & Pharmacology Authors: Hui Qi, Chen Kou, Yu-Jie Qi, Bo-Hao Tang, Yue-E Wu, Fei Jin, Xiao-Jing Luo, Yan-Hua Shen, Ya-Jie Guo, Xue Qi, Ya-Cui Wang, Qian Dong, Xing-Kai Chen, Hai-Yan Shi, Yi Zheng, Wei Zhao, A-Dong Shen Tags: Short Communication Source Type: research
More News: Child Development | Children | Drugs & Pharmacology | History of Medicine | Infectious Diseases | Superbugs